登录 | 注册    关注公众号  
搜索
 > 【CD45】

CD45信息

英文名称:Leukocyte common antigen
中文名称:白细胞共同抗原
靶点别称:PTPRC,T200,CD45,Protein Tyrosine Phosphatase, Receptor Type C,CD45 Antigen,L-CA,Protein Tyrosine Phosphatase, Receptor Type, C Polypeptide,Receptor-Type Tyrosine-Protein Phosphatase C,T200 Leukocyte Common Antigen,Leukocyte Common Antigen,T200 Glycoprotein,EC 3.1.3.48,CD45R,GP180,B220,LCA,LY5,Leukocyte Common Antigens,Protein Tyrosine Phosphatase Receptor Type C,EC:3.1.3.48
上市药物数量:0
临床药物数量:3
最高研发阶段:临床三期

CD45 分子别名

CD45,PTPRC,L-CA,T200

CD45 分子背景

CD45 is a receptor protein tyrosine phosphatase, also known as Ly-5 or leukocyte common antigen. CD45 mainly involves in the initiation of T cell receptor signaling by controlling the activation of the Src family protein-tyrosine kinases Lck and Fyn. CD45 deficiency causes in T- and B-lymphocyte dysfunction in the form of severe combined immune deficiency. It also takes a significant role in autoimmune diseases and cancer as well as in infectious diseases including fungal infections.

CD45 前沿进展

CD45临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
I-131-Apamistamab BC8-I-131; BC-8 临床三期 弗莱德哈钦森癌症研究中心 造血干细胞移植, 骨髓增生异常综合征, 急性髓细胞样白血病 详情
Immunomodulatory progenitor cell therapy (Celixir) 临床三期 Celixir 心内膜心肌纤维化, 心肌疾病 详情
At 211 MAb BC8-B10 临床二期 弗莱德哈钦森癌症研究中心 肿瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定